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Abstract
Background: The prognosis of hepatocellular carcinoma (HCC) varies following surgical resection and the large
variation remains largely unexplained. Studies have revealed the ability of clinicopathologic parameters and gene
expression to predict HCC prognosis. However, there has been little systematic effort to compare the performance
of these two types of predictors or combine them in a comprehensive model.
Methods: Tumor and adjacent non-tumor liver tissues were collected from 272 ethnic Chinese HCC patients who
received curative surgery. We combined clinicopathologic parameters and gene expression data (from both tissue
types) in predicting HCC prognosis. Cross-validation and independent studies were employed to assess prediction.
Results: HCC prognosis was significantly associated with six clinicopathologic parameters, which can partition the
patients into good- and poor-prognosis groups. Within each group, gene expression data further divide patients
into distinct prognostic subgroups. Our predictive genes significantly overlap with previously published gene sets
predictive of prognosis. Moreover, the predictive genes were enriched for genes that underwent normal-to-tumor
gene network transformation. Previously documented liver eSNPs underlying the HCC predictive gene signatures
were enriched for SNPs that associated with HCC prognosis, providing support that these genes are involved in
key processes of tumorigenesis.
Conclusion: When applied individually, clinicopathologic parameters and gene expression offered similar predictive
power for HCC prognosis. In contrast, a combination of the two types of data dramatically improved the power to
predict HCC prognosis. Our results also provided a framework for understanding the impact of gene expression on
the processes of tumorigenesis and clinical outcome.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in the world, accounting for approximately
one million deaths, with an increasing trend of new inci-
dences annually [1-3]. Surgical resection is regarded as
the standard curative treatment of HCC [3]. However,
prognosis following surgery varies substantially. This var-
iation becomes a hurdle in searching for effective and
efficacious therapies and cancer management strategies.
There is an ongoing search for predictive biomarkers of
cancer prognosis, where pathological parameters, protein
biomarkers, mRNA expression levels, and genomic DNA
abnormalities have been surveyed [4-9].
On two independent Hong Kong HCC cohorts that we
previously described [10], the HCC prognosis was signifi-
cantly associated with clinicopathologic parameters
including tumor size, number of tumor nodules (NOTN),
tumor stage (new AJCC and pTNM), venous infiltration
status, serum albumin level (ALBU), and serum a-feto-
protein level (AFP). These parameters were further sum-
marized into a linear score that was demonstrated to
partially predict disease-free survival ([DFS] time to
tumor recurrence) and overall survival (time to death)
[10]. A natural path to further enhance this prediction
model would be to incorporate molecular level biomar-
kers, for example, gene expression profiles in the tumor
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or adjacent normal tissues. Currently, such efforts have
been limited due to the availability of fresh frozen tissues
[4] forcing some studies to use paraffin-embedded
samples [9,11]. Most importantly, the search for gene sig-
natures should be conducted by conditioning on the clin-
icopathologic parameters, and focus on the identification
of novel variance components that improve the prognosis
prediction beyond that achieved by the clinicopathologic
features alone.
Herein we carried out a carefully designed search for
gene expression signatures underlying prognosis of HCC
using tumor and adjacent normal tissue expression pro-
files. We identify a gene expression signature that signif-
icantly enhances our ability to predict HCC prognosis.
Additionally, we demonstrate that this HCC prognosis
signature is related to widespread changes we previously
identified in the liver tissue network that are associated
with HCC, providing additional mechanistic insights
into tumorigenesis.
Methods
Study Subjects
A total of 272 HCC patients were included in the initial
training dataset. Resected tumor and adjacent non-tumor
liver tissues were collected from patients who had under-
gone hepatectomy for curative treatment of HCC at
Queen Mary Hospital, Pokfulam, Hong Kong between
1993 and 2007 [10]. Informed consents were obtained
from patients regarding to the use of the liver specimens
for research. Additional File 1, Table S1 summarized the
demographic and clinicopathologic features of these
patients. All samples came from individuals who provided
written informed consent to make their samples available
for scientific research. In addition, all of the samples and
patient data were approved for use in this study by IRBs
specific to each of the participating organizations. Experi-
mental research reported in this paper was also approved
by IRBs of each participating organizations. Research
reported in this paper was in compliance with the Helsinki
Declaration.
Pathology Parameter Measurements
The clinicopathologic features of the patients analyzed
were sex, age, tumor size, number of tumor nodules, cel-
lular differentiation according to the Edmondson classifi-
cation, venous infiltration without differentiation into
portal or hepatic venules, tumor node metastasis stage
(pTNM and AJCC), serum hepatitis B surface antigen
(HBsAg) status, and background liver disease in non-
tumorous liver tissue [12].
Sample processing to isolate RNA
Fresh frozen tissue was placed in a chilled milling tube
along with a stainless steel bead, dipped in a liquid
nitrogen bath and loaded onto the QIAGEN TissueLyser
for milling (30 Hz in 30 second intervals). Multiple
cycles of milling were sometimes required to achieve
complete pulverization of the tissue to a fine powder.
Isolation of RNA was achieved using the following pro-
cedures. The milled tissue samples were homogenized
in cryopreservation tubes using a Polytron with disposa-
ble rotostator probes. The tissue was homogenized in
750 to 1000 uL of 100% TRIzol. 100% Chloroform was
added to the TRIzol/GITC lysate (1:5 ratio) to facilitate
separation of the organic and aqueous components
using the phaselock (Eppendorf) system. The aqueous
supernatant was further purified using the Promega SV-
96 total RNA kit, incorporating a DNase treatment dur-
ing the procedure. Isolated total RNA samples were
then assayed for quality (Agilent Bioanalyzer) and yield
(Ribogreen) metrics prior to amplification.
RNA amplification and hybridization
Samples were amplified and labeled using a custom auto-
mated version of the RT/IVT protocol and reagents pro-
vided by Affymetrix. Hybridization, labeling and scanning
were completed following the manufacturer’s recommen-
dations (Affymetrix). Sample amplification, labeling, and
microarray processing were performed by the Rosetta
Inpharmatics Gene Expression Laboratory in Seattle,
WA. The expression data has been deposited in GEO
(GSE25097, http://www.ncbi.nlm.nih.gov/geo/).
Independent Validation Data Sets
Four recent studies were employed as independent valida-
tion. The first study consisted of 23 HCC tumor tissues
collected in Singapore and assayed on the Affymetrix Gen-
eChip HU133, resulting in the identification of a 57-gene
signature associated with tumor recurrence [4]. The sec-
ond study employed formalin-fixed paraffin-embedded
non-tumor (i.e., adjacent normal) liver tissues from 82
Japanese HCC patients. A 186-gene signature was derived
from this study using an Illumina array containing 6000
human genes [9]. The third study involved an HCC metas-
tases cohort from Asia (N = 115 normal tissues) in which
an Incyte 9, 180-reporter two channel array was used to
profile the normal liver tissues [13]. Finally, a China-
Belgium study (sample size N = 90) of mostly tumor tis-
sues was profiled on a Qiagen 70-mer two channel array
[14].
Statistical Analysis
Classification of patients into good and poor prognosis
groups
Prediction of cancer prognosis was performed by using
the clinicopathologic phenotypes recorded at the time of
surgery. There are a number of statistical learning techni-
ques able to serve as classifiers. However, many of these
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methods do not directly accommodate two-dimensional
outcome (e.g. survival and DFS). Herein, application of a
univariate parameter selection and multivariate Cox
model classifier was employed [6,7]. Univariate Cox
regression models were applied to search for clinico-
pathologic parameters associated with outcomes. All sig-
nificant clinicopathologic parameters were included in a
multivariate Cox model. The use of the model yields the
relative hazard for each patient, which serves as the linear
predictor for survival endpoints and further division of
the patients into good and poor prognosis groups based
on the linear predictor. This approach and its prediction
power were assessed using a leave-one-out (LOO) proce-
dure and an independent testing sample set also collected
in Hong Kong [10].
Expression trait processing
The intensity of all gene array experiments were nor-
malized together using RMA methods [15]. Afterwards,
the intensity was adjusted for gender and age of the
patients. To avoid the influence of outliers, we fit the
robust linear model (rlm, M-estimation with Tukey’s
bisquare weights), and used the residuals as the gene
expression trait in all following analysis.
Further Classification of good and poor prognosis groups
using gene expression
We examined whether the clinicopathologic phenotypes
that were recorded at the time of surgery might predict
cancer prognosis. Again, we applied the univariate Cox
model for feature selection and multivariate Cox model
for classification/prediction. Importantly, the classifier
should use both the clinicopathologic parameters and
expression biomarkers. As discussed above, feature selec-
tion on the entire dataset firstly identified genes that
associate with cancer stage, which are of significant scien-
tific value. However, these genes may not improve the pre-
diction performance since they carry information that is
redundant with the clinicopathologic data. Further, in the
good and poor prognosis groups defined by the clinico-
pathologic parameters, the gene signatures were likely to
be different. Therefore, we conducted the feature selection
in the two prognosis groups separately.
In brief, the univariate Cox regression models was
applied to search for gene expression traits associated
with outcomes. The top 100 genes were included in a
multivariate Cox model as the prediction model. Given
there are only slightly more than 110 patients in either
the good or poor prognosis groups, a linear model with
100 regressors would be unstable. Therefore, we con-
ducted a further reduction in dimensionality using prin-
ciple component analysis (PCA), a common approach to
handle gene expression data in prognosis predictions [7].
The primary motivation for this approach was the fact
that the top 100 genes are correlated; therefore, the top
principle components (PCs) are able to extract most of
the information and only cost a few degrees of freedom
in the linear model. The top 6 PCs were used to build the
Cox model for prediction, since they on average
explained 80% of the variation in the 100 genes. We also
explored additional models varying the number of genes
(e.g. 50 and 200) and number of PCs (e.g., 5), and the
results were consistent. From the model, we derived the
relative hazard for each patient, which serves as the linear
predictor for survival endpoints [10]. Further, we divided
the patients into two sub-groups using the linear predic-
tor, and the performance of the prediction was assessed
by a leave-one-out (LOO) procedure. In each LOO itera-
tion, we reserved one patient for testing and used the
remaining patients (say N-1 patients) for training. On
these N-1 training patients, we ran the univariate Cox
model on each gene and derived the pvalue for associa-
tion between prognosis (e.g. survival) and the gene’s
expression value. We then picked 100 genes with the
smallest pvalues. With the 100 genes over N-1 patients,
we constructed the 6 PCs, which then served as indepen-
dent variables in a multivariate Cox model. This model
and its coefficients captured the association between
HCC prognosis and the PCs. Next, we projected the gene
expression values of the reserved patient on the PC space
(defined on the training patients) to obtain the coordi-
nates of the first 6 PCs. We plugged these 6 coordinates
into the multivariate Cox model and calculated the rela-
tive hazard for the reserved testing patient. After N LOO
iterations, we derived the relative hazard for every
patient, which was actually the linear predictor. Lastly,
we used the log-rank test and Kaplan-Meier plot to
examine and visualize the performance of the linear pre-
dictor. This scheme is similar to a previous report using
clinicopathologic parameters to predict HCC outcome
[10], except for the extra step of PCA dimensionality
reduction.
Results
Clinicopathologic parameters predict HCC prognosis
Tumor and adjacent non-tumor liver tissues were col-
lected from 272 Chinese HCC patients who received cura-
tive surgery (referred to here as the HCC cohort).
Additional File 1 Table S1 summarizes the characteristics
of this cohort. Nearly 2/3 of the patients were right-cen-
sored (67.8%) and the other 1/3 (32.2%) of the patients
were deceased (failure) upon data analysis. Half of the
patients (51.1%) suffered from tumor recurrence during
the follow-up period. The primary endpoints (overall sur-
vival and DFS) were found to be significantly associated
with tumor size, AFP, ALBU, venous infiltration, pTNM
and new AJCC stage, and NOTN. Previous analysis has
shown that these clinicopathologic parameters can classify
patients in the HCC cohort into two groups (denoted as
good and poor prognosis groups) that give rise to distinct
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clinical outcomes [10]. For the survival endpoint, the good
and poor survival groups contained roughly equal num-
bers of patients and were significantly different with
respect to clinical outcome (log-rank test p-value of 6.0E-
6; Figure 1 left panels). The linear predictor (h) shown in
Figure 1 was derived using a leave-one-out (LOO) cross
validation procedure to reduce biases that result from over
fitting. Similarly, we classified the patients into good-DFS
and poor-DFS groups (log-rank test p-value = 5.6E-9,
Figure 1 right panel) [10]. Within each survival or DFS
group, the clinicopathologic parameters could not further
partition patients into subgroups of significantly different
prognosis. In other words, the variation of prognosis
within each group was not explained by clinicopathologic
parameters.
Combination of clinicopathologic and gene expressional
biomarkers enhances prediction
To advance our understanding of the molecular pro-
cesses and to extend the predictive power of the clinico-
pathologic variables, we explored the relationship of
gene expression to outcome. Tumor and adjacent nor-
mal tissues were profiled using the Affymetrix whole
genome expression array. The experiment surveyed 37,
585 unique transcripts, among which 23, 788 were
mapped to well-annotated genes. Using the gene expres-
sion traits to predict group membership, we observed
similar predictive power as was achieved using the clini-
copathologic parameters alone.
In order to identify biomarkers that further enhance
prognosis prediction based on the clinicopathologic para-
meters, a stratified analysis using univariate gene expres-
sion feature screening was carried out within each
prognosis group (Figure 1 & 2). Under the null hypoth-
esis the pvalues generated by this screening should follow
a uniform distribution, substantial enrichment of low
pvalues indicated a large number of prognosis-associated
genes that might offer predictive power, shown Addi-
tional File 2 Figure S1. However, many of the prognosis-
associated genes captured the same information as the
clinical parameters, and contributed no extra prediction
power. In the stratified analysis, we were able to identify
genes associated with survival or DFS in each prognosis
group. For example, many genes in the tumor tissue were
associated with survival in the good-survival group but
not in the poor-survival group (Additional File 3 Figure
S2), suggesting that tumor gene expression may further
enhance prognosis prediction in the good-survival group
but not the poor-survival group. Interestingly, there were
many normal tissue gene expression traits associated
with DFS in the good DFS group, while many tumor tis-
sue gene expression traits associated with DFS in the
poor DFS groups (Additional File 3 Figure S2), again sug-
gesting that the gene expression data may help stratify
patients according to DFS beyond what could be
achieved by the clinicopathologic parameters alone.
Motivated by these results, we combined the gene
expression data with the clinicopathologic parameters to
Figure 1 Clinicopathologic Parameters Predict Survival and DFS on Patients with Available Normal Tissue Gene Expression Data. In the
left panels, the clinicopathologic parameters can classify the Hong Kong HCC patients into the good prognosis and poor prognosis groups that
have distinct survival outcome. Similarly, in the right panels, we also classify the patients into two groups of distinct disease-free survival (DFS).
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construct models to predict HCC prognosis and com-
pare to those models constructed from the clinicopatho-
logic data alone. We again employed a LOO cross
validation strategy in each subset of patients to mini-
mize over-fitting. For example, in the good-survival
group, the LOO procedure was performed on the 113
patients with available normal tissue gene expression
data (Figure 3, left panel).
The normal tissue expression data improved the pre-
diction for the good-survival group (p-value = 0.011,
Figure 3 left panel). The blue line in Figure 3 repre-
sented an excellent survival function (over 90%) for a
group of patients carrying both favorable clinicopatholo-
gic and gene expression profiles. The same procedure
was conducted on the 117 patients in the poor-survival
group with available normal tissue gene expression data.
As expected, the expression data could not further
improve the predictive power of the model (Figure 3,
right panel). Prediction in the good-DFS (p-value =
0.0027), but not the poor-DFS group was also further
improved by incorporating normal tissue expression
data into the model (Figure 4).
We carried out the same analysis just described using
the tumor tissue expression data. It was noted that the
sample sizes of the tumor tissue analysis was different
from that of normal tissue (Figure 1&2). Figure 5 shows
that the prediction in the good-survival (p value = 9.0E-
4) and poor-survival (p-value = 0.0023) groups were
further improved by the incorporation of the tumor
expression data. Curiously, the pattern was opposite for
DFS compared to what we observed in the normal tis-
sues. For the poor-DFS group, tumor expression signifi-
cantly further partitioned patients into good and poor
DFS subgroups (p-value = 5.5E-8; Figure 6, right panel).
No prediction improvement for the good-DFS group
was observed. Since both normal and tumor tissues had
predictive power in the good-survival group (Figure 3
and 5), we were motivated to explore predictive models
incorporating expression traits from both tissue types.
The number of patients with both tissues available was
N = 110. The combined data resulted in a further
improvement of the prediction performance (Additional
File 4 Figure S3).
Independent validation using published HCC prognosis
gene signatures
The identification of prognosis-associated gene signatures
in HCC is an active field of research, with previous reports
indicating that different gene signatures may be harvested
from tumor and adjacent non-tumor tissues [4,9,13,14,16].
To capture information from the expression data that was
not yet covered by the clinicopathology, the clinicopatho-
logic parameters should be conditioned on during the
search for expression signatures, as we have done. Unfor-
tunately, many of the reported studies did not follow such
a strategy. Ideally, our gene signatures would be tested in
independent HCC cohorts. However, raw clinical outcome
data was not available for any of the published studies
Figure 2 Clinicopathologic Parameters Predict Survival and DFS on Patients with Available Tumor Tissue Gene Expression Data. In the
left panels, the clinicopathologic parameters can classify the Hong Kong HCC patients into the good prognosis and poor prognosis groups that
have distinct survival outcome. Similarly, in the right panels, we also classify the patients into two groups of distinct disease-free survival (DFS).
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[4,9,13,14]. Therefore, we compared our gene signature,
which showed predictive value towards HCC prognosis,
with published signatures. We would not expect perfect
concordance among the signatures given the different
patient recruitment criteria, experimental conditions, array
platforms, and statistical methods across the studies. For
example, five different array platforms were used in studies
listed in Table 1 and 2: Affymetrix whole genome custom
Figure 3 Normal Tissue Expression Predicts Survival. Within the good prognosis and the poor prognosis groups, clinicopathologic
parameters could no longer separate patients into partitions of different survival outcome. Meanwhile, adjacent normal tissue gene expression
provided extra information to further refine the prognosis prediction. Using a LOO framework with the dimension reduction and multivariate
Cox model, we assigned predicted hazard for each patient. The hazard was able to further separate the good prognosis group, but not the poor
prognosis group.
Figure 4 Normal Tissue Expression Predicts DFS. Using adjacent normal tissue gene expression data, we derived the predicted hazard within
the good and poor DFS groups. The predictor (predicted hazard) further separated the patients in the good prognosis group, but not in the
poor prognosis group.
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array (current study), Illumina 6000-gene human array [9],
Qiagen 70-mer two channel array [14], Incyte 9, 180-
reporter two channel array [13], and Affymetrix GeneChip
HU133A&B arrays [4]. More importantly, since the sam-
ple sizes for the published studies were all small (n < 200),
the power to capture prognosis-associated genes was low.
Hence, we applied liberal p-value cutoffs (e.g. 5E-4) in
order to capture a majority of the HCC prognosis-asso-
ciated genes and in turn enhance the comparison to the
published signatures (Table 1, 2 and Additional File 5
Table S2). The survival- and DFS-signatures we identified
significantly overlapped with all published gene lists
(Table 1). For example, Lee et al reported a comprehensive
HCC gene signature on a Chinese-Belgium dataset that
Figure 5 Tumor Tissue Expression Predicts Survival. Using tumor tissue gene expression profile, we obtained the predicted hazard within the
good survival and poor survival groups. The predictor further separated the patients in both the good survival and the poor survival groups.
Figure 6 Tumor Tissue Expression Predicts DFS. Using tumor tissue gene expression profile, we obtained the predicted hazard within the
good DFS and poor DFS groups. The predictor further separated the patients in poor DFS group, but not in the good DFS groups.
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overlapped our results in a highly significant manner (4.8
fold enrichment; Fisher Exact Test p-value = 1.4E-12 for
the tumor tissue DFS signature, Table 1 and 2). As one
would expect, when the study design of a published gene
signature matches our design, we observed a more exten-
sive overlap with the signatures. For example, Hoshida
et al. [9] and Budhu et al. [13] studied adjacent non-tumor
liver tissues in HCC patients. Their gene lists overlapped
with our normal tissue signature more significantly than
with the tumor signature. Alternatively, Lee et al. reported
a gene list that overlapped heavily with our tumor tissue
signatures. It is noteworthy that the hypergeometric test
p-values were driven by both magnitudes of overlaps and
the size of the published gene lists. The overlap among the
various gene lists were summarized in Additional File 6, 7,
8 and 9, Table S3. The first part of Additional File 5, 6, 7,
and 8, Table S3 highlighted genes that reached genome-
wide significance in our HCC data. There was no adjust-
ment for clinicopathologic parameters in order to retain
consistency with other published signatures. A strict cutoff
(Cox p-value ≤ 2e-6) was applied to the identified genes
that were genome-wide significant after a Bonferroni
correction. The second part of Additional File 6, 7, 8 and
9, Table S3 summarized genes that appeared in at least
two other gene lists.
eSNPs underlying differentially connected genes linked to
HCC prognosis
To explore the predictive genes in the context of a normal-
to-tumor network reconfiguration, we looked at whether
the genetic perturbations of the predictive genes were asso-
ciated with HCC prognosis. Two sets of genes were
explored in this way: 1) genes differentially connected
between the normal and tumor tissue co-expression net-
works (gene-set-1), as detailed by Lamb et al [17]; and 2)
genes whose expression levels were significantly associated
with copy number abnormalities (CAN) in the tumor tis-
sue (gene-set-2).
To explore whether these gene sets were enriched for
eSNPs that associate with HCC prognosis, we genotyped
DNA isolated from adjacent normal tissues using the
Illumina 650Y SNP arrays and characterized the genetic
architecture of gene expression based on a previously
described method [18]. This genome-wide association
Table 1 Using Independent HCC Studies to Validate HKU Gene Signature Identified at 0.0005 Level*
HKU Gene Signature in Normal Tissue
Survival (1074 HKU Gene Signature) ‡
Overlapping Genes Enrichment p-value
Japanese Gene Signature 33 4.8E-13
Chinese-Belgium Gene Signature 41 1.1E-13
Asia HCC Metastases Gene Signature 31 1.0E-5
Singapore Gene Signature 5 1.2E-2
Disease Free Survival (1195 HKU Gene Signature)
Overlapping Genes Enrichment p-value
Japanese Gene Signature 34 1.9E-12
Chinese-Belgium Gene Signature 36 2.7E-9
Asia HCC Metastases Gene Signature 36 8.1E-7
Singapore Gene Signature 5 1.9E-2
HKU Gene Signature in Tumor Tissue
Survival (660 HKU Gene Signature)
Overlapping Genes Enrichment p-value
Japanese Gene Signature 5 0.36
Chinese-Belgium Gene Signature 22 4.6E-7
Asia HCC Metastases Gene Signature 6 0.13
Singapore Gene Signature 1 0.11
Disease Free Survival (2169 HKU Gene Signature)
Overlapping Genes Enrichment p-value
Japanese Gene Signature 6 0.12
Chinese-Belgium Gene Signature 28 1.4E-12
Asia HCC Metastases Gene Signature 20 1.6E-5
Singapore Gene Signature 1 0.27
*Herein, we compared gene signatures obtained in following studies: HKU study (sample size N = 229 for adjacent normal tissues and N = 267 for tumor tissues),
Japan study (175 gene signature based on sample size N = 82), Asia HCC Metastases study (307 gene signature based on sample size N = 115), China-Belgium
study (247 gene signature based on sample size N = 90) and Singapore study (43 gene signature based on sample size N = 23).
‡We selected genes associated with survival or disease-free survival using nominal p-value of 0.01.
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study of gene expression resulted in 1, 296 cis expression
QTLs (eQTLs) [18] at a 10% FDR (translating to p-value
cutoff = 9E-6). We termed the significant SNPs (asso-
ciated with the corresponding expression trait at a p <
9E-6) underlying the eQTLs as eSNPs. There were 707
and 2, 840 eSNPs for gene-set-1 and gene-set-2, respec-
tively. Further, we examined if the eSNPs linked to gene-
set-1 and -2 were enriched for SNPs that associated with
clinical endpoints (referred to as clinical SNPs or cSNPs).
In brief, the cSNPs were identified using Cox models
focusing on survival or DFS. The model was adjusted for
clinicopathologic parameters.
At an a level of 0.01, we identified 6, 399 cSNPs asso-
ciated with HCC survival (referred to as survival-cSNPs).
Interestingly, the eSNPs underlying gene-set-1 were 2.1-
fold enriched for survival-cSNPs (p = 7E-4); and the
eSNPs underlying gene-set-2 were 1.7-fold enriched for
survival-cSNPs (p = 2E-5). In parallel, at an a level of
0.01, the SNP screening using a Cox model yielded 5, 246
SNPs associated with DFS (referred to as DFS-cSNPs).
We found the eSNPs underlying gene-set-1 were not
enriched for DFS cSNPS; in contrast, eSNPs for gene-set
2 were 1.9-fold enriched for DFS cSNPs (p-value = 5E-7).
For comparison, we randomized the clinical endpoints
and repeated the Cox modeling, and at a level of 0.01,
we yielded pseudo-cSNPs, which arose purely from type I
errors. The eSNPs underlying gene-set-1 and -2 were not
enriched in the pseudo-cSNPs.
Discussion
Numerous studies have reported the ability of clinico-
pathologic parameters [2,3,10,19] and gene expression
traits [4,9,13,14] to predict HCC prognosis. However, the
sample sizes of these previous studies were small, and
there were no systematic efforts to compare the perfor-
mance of these two types of predictors or combine them
in one unified model. As we previously showed, several
clinicopathologic parameters that are easily and routinely
measured, provided excellent predictive power for out-
come in HCC [10] and result in predictions that were
readily applicable to clinical practice. Given their utility,
it is natural to attempt to further enhance the clinico-
pathology-based prediction model by adding gene
expression data. We conducted a head-to-head perfor-
mance comparison between gene expression predictors
derived from normal and tumor tissue (denoted as hgene-
expression) vs. predictors derived solely from clinicopathol-
ogy (hpathology; Materials and Methods) and benchmarked
Table 2 Using Independent HCC Studies to Validate HKU Gene Signature Identified at 0.05 Level
HKU Gene Signature in Normal Tissue
Survival (7400 HKU Gene Signature) ‡
Overlapping Genes Enrichment p-value
Japanese Gene Signature 92 1.1E-9
Chinese-Belgium Gene Signature 133 3.1E-14
Asia HCC Metastases Gene Signature 144 2.0E-9
Singapore Gene Signature 19 2.4E-2
Disease Free Survival (7661 HKU Gene Signature)
Overlapping Genes Enrichment p-value
Japanese Gene Signature 96 1.8E-10
Chinese-Belgium Gene Signature 131 3.6E-12
Asia HCC Metastases Gene Signature 145 1.3E-8
Singapore Gene Signature 21 7.6E-3
HKU Gene Signature in Tumor Tissue
Survival (5403 HKU Gene Signature)
Overlapping Genes Enrichment p-value
Japanese Gene Signature 66 2.4E-6
Chinese-Belgium Gene Signature 142 5.5E-33
Asia HCC Metastases Gene Signature 97 1.2E-4
Singapore Gene Signature 19 4.9E-4
Disease Free Survival (4377 HKU Gene Signature)
Overlapping Genes Enrichment p-value
Japanese Gene Signature 58 9.1E-7
Chinese-Belgium Gene Signature 131 1.7E-35
Asia HCC Metastases Gene Signature 89 1.9E-6
Singapore Gene Signature 15 2.8E-3
‡We selected genes associated with survival or disease-free survival using nominal p-value of 0.05.
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them in a LOO framework (Figure 1, 2 and Additional
File 10 Figure S4). Please note, the genes used in the pre-
diction models might be different with regard to normal
vs. tumor tissue expression, as well as in each LOO itera-
tion. Overall, hgene-expression and hpathology performed simi-
larly. The hgene-expression of tumor tissue was better than
hpathology in predicting DFS, but hgene-expression slightly
underperformed hpathology in all other scenarios. Overall,
gene expression was not superior to clinicopathology in
predicting prognosis. One reason might be that gene
selection primarily identified genes correlated with clini-
copathologic parameters (e.g. cancer stage). To assess if
expression variables could be identified that enhance pre-
dictive power, stratified analysis and computed hgene-
expression within the good- and poor subgroups that go
beyond the clinicopathologic parameters were performed.
A combination of these two types of data resulted in the
identification of a group of patients with near perfect sur-
vival after surgery (blue curve, left panel, Figure 3). These
patients had both favorable clinicopathologic and gene
expression profiles (they enjoyed a 90% survival rate over
100 months). In contrast, we found that DFS over
30 months for patients with both poor clinicopathologic
and gene expression profiles whose was lower than 10%.
The focus of this study is stratified modeling, which is a
natural extension of our previous work. Alternatively, we
can build a single model incorporating clinicopathologic
parameters and gene expression data simultaneously
(Additional File 11 Figure S5). The prediction framework is
identical to the above analyses except the multivariate Cox
model included both the clinicopathologic parameters and
the top 6 PCs. In the gene selection step we also included
clinicopathologic parameters in the Cox model and then
picked 100 genes with the smallest pvalues. The overall
prediction was better than using gene expression alone
(Additional File 10 Figure S4), indicating clinicopathology
captured valuable information beyond gene expression.
However, comparing to Figure 1 and 2, adding gene
expression only enhanced prediction in one scenario
(tumor gene expression improved the prediction of survi-
val). A possible explanation would be that different gene
sets were associated with prognosis across the strata
defined by clinicopathology, and these gene sets offer var-
ious prediction value. For example, shown in Figure 2, nor-
mal tissue expression was used in prediction in the good-
survival stratum but not the poor-survival stratum. In the
single model approach, genes with little prediction value
also entered the model, bringing noise and reducing the
performance. Lastly, we also evaluated a single model
incorporating clinicopathologic parameters, and expression
profiles of both normal and tumor tissue (Additional File
12 Figure S6). We reduced the expression profile of each
tissue to 6 PCs, therefore, a total of 12 PCs entered the
model. Overall, such models did not greatly outperform
the models based on clinicopathology alone (Figure 1&2)
or models based on clinicopathology and expression pro-
files (Additional File 11 Figure S5). Again, this lack of
improvement could be attributable to noises introduced
into the prediction.
HCC tumor tissue and adjacent non-tumor tissues har-
bor distinct prognosis-associated signatures and lead to
differences in predictive power. Importantly, we noted
that the gene signature derived from the tissues signifi-
cantly overlapped. Consistent findings were also reported
on Chinese and Belgium HCC patients [14], Asian [13]
and Singapore patients [4]. However, for 82 Japanese
patients, Hoshida et al found gene-expression profiles of
tumor tissue failed to yield a significant association with
survival [9]. This result is inconsistent with the fact that
gene expression traits in tumor tissues were correlated
with cancer stage, and cancer stage was strongly asso-
ciated with survival [10]. The failure to detect gene
expression traits with predictive power in this instance
could be due to the small sample size (N = 82) and the
use of formalin-fixed, paraffin-embedded tissues [9].
The mechanistic basis whereby gene expression traits
predict the aggressiveness of a tumor remains to be
defined. One of the striking features of this analysis and
others [4,9,13] was the finding that signatures in normal
tissue adjacent to the tumor is highly predictive of prog-
nosis. It had been suggested that mechanistically these sig-
natures represented a so called “field-effect” capturing
damage to liver tissue and the state of inflammation
related to the likelihood of subsequent tumors arising
[9,20]. In other words, the field effect hypothesis implied
that the signatures did not relate directly to processes in
the tumors per se but rather the environment from which
tumors might arise. An alternate hypothesis supported by
our results was that the signatures are mechanistically
connected to tumor specific events in some way, given the
genes associated with survival (p < 2e-159, fold enrich-
ment 31.01) and DFS (p < 5e-152, fold 29.31) in adjacent
normal and in tumor tissues significantly overlap.
To address whether the “field effect” or this alternate
hypothesis was better supported by the data, we first
examined the evidence that tumors directly affect the
surrounding normal tissues via secreted factors. If that
were the case we would expect that the adjacent normal
gene expression patterns would be correlated with DNA
copy number abnormalities (CNA) in the tumor tissue,
given we previously showed CNA was strongly con-
nected to tumor gene expression [10]. No significant
associations beyond what would be expected by chance
were found. We were also able to exclude significant
invasion of tumor cells into the adjacent normal tissues
given we observed no significant associations between
normal tissue derived CNA and normal tissue gene
expression [10].
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Given this result, how might signatures in normal tissues
mechanistically relate to tumor events? Herein, we took
advantage of previous work on this dataset. We described
the massive gene expression network changes that occur
during HCC tumorigenesis, and such rearrangements
were likely driven by tumor CNA [10]. In brief, we defined
gene pairs where the pair was significantly correlated in
one setting and significantly less correlated in another
[10]. Using stringent cut-offs, there were 8, 736 genes dif-
ferentially connected between the adjacent normal and
tumor tissues with ~86% of cases representing a loss of
connectivity in the tumor (LOC) and the remaining ~14%
representing a gain of connectivity (GOC) [10]. We there-
fore tested whether the predictive gene expression traits
from the adjacent normal tissue were enriched for differ-
entially connected genes and found that indeed they were.
The genes associated with survival in adjacent normal tis-
sue (Cox p < 0.01, Additional File 6, 7, 8 and 9, Table S3)
were enriched for genes participating in differential con-
nections (p < 1.98e-80, fold enrichment 2.69). Similarly
gene expression traits in adjacent normal tissue associated
with DFS (Cox p < 0.01, Additional File 6, 7, 8 and 9,
Table S3) were enriched for genes identified as differen-
tially connected in the tumor tissue (p < 5.2e-69, fold
2.52).
Our previous reports also documented that a large frac-
tion of expression variation can be explained by CNA in
the tumor tissues [10]. Therefore, we asked if the predic-
tive genes (Additional File 6, 7, 8 and 9, Table S3) were
enriched for genes that associated with cis-acting CNAs in
tumors. We found that both survival- and DFS-associated
genes in normal tissue were enriched for genes associated
with CNAs in cis in the tumor tissue (p-values were 2.99e-
8 and 1.72e-11, respectively). Since genes in adjacent nor-
mal tissues were measured entirely separately from genes
in the tumor, there was no a priori reason for them to
behave similarly unless there was a mechanistic connec-
tion. We found that predictive genes from adjacent normal
tissue were selectively enriched in network re-arrange-
ments and enriched for genes that associate with CNA
associated tumorigenesis, strongly suggesting that these
genes represent important functions targeted for alteration
in tumors. Stated in another way, the predictive signatures
in adjacent normal tissue are a measure of the ability of
the tissue to alter expression networks to enter a more
aggressive state.
If the predictive genes were the determinant of the nor-
mal-to-tumor network reconfiguration, then we would
expect that genetic perturbations of these genes would
also be associated with HCC prognosis. We examined the
normal liver tissue eSNPs underlying two sets of genes (1)
genes that are differentially connected between the normal
and tumor states in the HCC cohort, and (2) genes whose
expression levels were significantly explained by CNA in
the liver tumor tissue. We found that the eSNPs control-
ling the expression level of these two sets of genes were
enriched for association with HCC survival and DFS. This
result supports the hypothesis that the mechanisms by
which genes in normal tissue are predictive of prognosis
reflects their ability to facilitate the transition from a nor-
mal tissue network to a tumor network, where this transi-
tion determines cancer progression.
We have demonstrated the excellent predictive power of
our approach by combining clinicopathologic parameters
and gene expression profiles. As a result, we expect that
this approach to provide valuable guidance for HCC treat-
ment/management in clinical practice. More importantly,
based on our previous work on the architecture of coex-
pression networks in adjacent normal and tumor tissues
[10], we proposed a general mechanism of how predictive
genes influence HCC prognosis. The massive rearrange-
ment of expression networks plays a central role in HCC
progression, which was reflected in the ability of such
genes to predict HCC prognosis. This also explained why
the predictive genes significantly overlapped between the
adjacent normal and tumor tissues, since such genes
would ostensibly continue to reflect the ongoing altera-
tions in network state.
Conclusions
Hepatocellular carcinoma (HCC) is highly lethal, and its
prognosis following surgery varies substantially, in a man-
ner which is yet to be explained. Our contributions to
understanding the progression of HCC are three fold. (1)
We established a comprehensive algorithm to incorporate
clinicopathologic and gene expression parameters, which
greatly improves the prediction of HCC prognosis. (2)
Using a large sample size, we characterize the gene expres-
sion alternation in HCC tumor and adjacent normal tis-
sues, and their association to overall survival and disease-
free survival. (3) We proposed a general framework
explaining why gene expression in both tumor and adja-
cent normal tissues can predict HCC prognosis. In brief,
the gene expression networks undergo massive a transition
during tumorigenesis and tumor progression, where nor-
mal tissue gene networks are destroyed and tumor gene
networks are establish. States of the genes in these key
networks determine the likelihood and rate of such mas-
sive transition as well as tumor progression and as a result
the expression levels of these genes predict HCC
prognosis.
Additional material
Additional file 1: Supplementary. Supplementary Table 1
Additional file 2: Figure S1. Crude Pvalues of Association between
HCC Prognosis and Gene Expression Profiles. Histogram of p-values
of the univariate search for genes associated with survival outcome. The
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substantial enrichment for small p-values indicated potential predictive
power of the gene expression data.
Additional file 3: Figure S2. Association between HCC Prognosis
and Gene Expression Profiles in Strata Defined by Clinicopathologic
Parameters. Histogram of p-values of the univariate search for genes
associated with HCC outcome, conducted within good and poor
prognosis strata.
Additional file 4: Figure S3. Improving prediction in the good-
survival stratum using normal tissue and tumor tissue gene
expression profiles together. Shown in Figure 2 and 4, both normal
tissue and tumor tissue had prediction value in the good-survival group.
Restricted in the patients with both normal and tumor tissues available
(N = 110), we followed LOO procedure and derived h incorporating
expression data of both tissue. The prediction performance was further
improved. Presented in the blue curve (lower right panel), we identified
55 patients with excellent clinicopathologic and gene expressional
profiles (both normal and tumor tissues). Their 100 months survival was
above 95%.
Additional file 5: Supplementary. Supplementary Table 2
Additional file 6: We integrated the Hong Kong gene list with
published HCC gene signatures and create the list of HCC
prognosis-associated genes. The first part of the list contains genes
that reached genome-wide significance level in our Hong Kong data.
Herein, we did not adjust for clinicopathologic parameter in order to
remain comparable to published signatures. Strict cutoff (Cox p-value ≤
2e-6) were applied to our results, therefore, the identified genes were
genome-wide significant after Bonferroni correction. The second part of
the list contains genes that appeared at least twice in HCC gene lists.
Here, we applied a liberal p-value cutoff (Cox p-value ≤ 0.01) to Hong
Kong data. The second column of the table presents the Wald’s test p-
values, where “-” denotes the p-value above 0.01. The columns 3-6 are
indicators for published HCC signatures, where “1” denotes present and
“-” denotes absent.
Additional file 7: Supplementary Table 3B
Additional file 8: Supplementary Table 3C
Additional file 9: Supplementary Table 3D
Additional file 10: Figure S4. Predicting HCC Prognosis using Gene
Expression Profiles of Normal of Tumor Tissue
Additional file 11: Figure S5. Predicting HCC Prognosis using
Clinicopathologic Parameters + Gene Expression Profiles of Normal or
Tumor Tissue
Additional file 12: Figure S6. Predicting HCC Prognosis using
Clinicopathologic Parameters + Gene Expression Profiles of Both Normal
and Tumor Tissue
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